{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:33:30Z","timestamp":1777480410574,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2022,1,13]]},"abstract":"<jats:p>BACKGROUND: Dysregulated apoptosis is a hallmark of cancer development and progression. TRAIL and its receptors (R1 and R2) are key players in the extrinsic apoptotic pathway. Genetic alteration or blockade of TRAIL-R1 may alter its apoptotic function, and subsequently provide growth advantage to neoplastic cells. OBJECTIVE: to investigate the possible association between -C626G, -A683C and -A1322G single nucleotide polymorphisms (SNPs) of TRAIL-R1 gene and the susceptibility to B-NHL in a cohort of Egyptians. METHODS: Genotypic analysis was performed for 100 newly diagnosed B-NHL patients and 150 age and gender matched healthy controls. RESULTS: The polymorphic alleles of -C626G and -A1322G conferred almost twofold increased risk of B-NHL (OR = 1.76; 95%CI = 1.01\u20133.22 and OR = 1.89; 95%CI = 1.01\u20133.75 respectively). There was no statistical difference in the distribution of TRAIL-R1-A683C alleles\/genotypes between B-NHL patients and controls. B-NHL risk increased when -C626G and -A1322G polymorphic genotypes were co-inherited (OR = 3.57; 95%CI = 1.29\u20139.84). The risk conferred by -C626G SNP increased for DLBCL (OR = 3.39, 95% CI: 1.61\u20137.16). CONCLUSION: TRAIL-R1\u2013C626G and -A1322G polymorphisms could be considered as molecular risk factors for B-NHL especially DLBCL. The data provided by the current study constitute an initial millstone towards developing a large-scale dataset for genetic variations that could contribute to lymphomagenesis in Egyptian population.<\/jats:p>","DOI":"10.3233\/cbm-201786","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:22:59Z","timestamp":1626186179000},"page":"451-458","source":"Crossref","is-referenced-by-count":2,"title":["Genetic variations in tumor necrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt1"],"prefix":"10.1177","volume":"32","author":[{"given":"Mervat","family":"Khorshied","sequence":"first","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nohair","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Khorshid","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa","family":"Bakr","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology\/Hematology, Faculty of Medicine, Fayoum University, Fayoum, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-201786_ref1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.3233\/CBM-201786_ref2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.20045","article-title":"Cytotoxic T-Lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin\u2019s lymphoma","volume":"76","author":"Monne","year":"2004","journal-title":"Am J Hematol"},{"key":"10.3233\/CBM-201786_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","article-title":"Epidemiology of non-Hodgkin\u2019s lymphoma (NHL): trends, geographic distribution, and etiology","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.3233\/CBM-201786_ref4","doi-asserted-by":"crossref","unstructured":"A.S. Ibrahim, H.M. Khaled, N.H. Mikhail et al., Cancer incidence in Egypt: Results of the national population-based cancer registry program, J Cancer Epidemiol (2014): Article ID\u00a0437971.","DOI":"10.1155\/2014\/437971"},{"issue":"7","key":"10.3233\/CBM-201786_ref5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3324\/haematol.11011","article-title":"Genetic susceptibility to lymphoma","volume":"9","author":"Skibola","year":"2007","journal-title":"Haematologica"},{"key":"10.3233\/CBM-201786_ref6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"10.3233\/CBM-201786_ref7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","article-title":"TRAIL signalling: Decisions between life and death","volume":"39","author":"Falschlehner","year":"2007","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.3233\/CBM-201786_ref8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nature Reviews Cancer"},{"key":"10.3233\/CBM-201786_ref9","doi-asserted-by":"crossref","unstructured":"P. Geng, J. Li, N. Wang, Y. Liao, J. Ou et al., Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility, Scientific Reports 5 (2015), Article number: 10382.","DOI":"10.1038\/srep10382"},{"key":"10.3233\/CBM-201786_ref10","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia","volume":"21","author":"MacFarlane","year":"2002","journal-title":"Oncogene"},{"key":"10.3233\/CBM-201786_ref11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(03)01225-7","article-title":"Chromosome arm 8p and cancer: a fragile hypothesis","volume":"4","author":"Birnbaum","year":"2003","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.3233\/CBM-201786_ref12","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2005-05-2013","article-title":"Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes","volume":"106","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"key":"10.3233\/CBM-201786_ref13","first-page":"1688","article-title":"Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer","volume":"7","author":"Fisher","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-201786_ref14","first-page":"1157","article-title":"Death receptor 4 and bladder cancer risk","volume":"63","author":"Hazra","year":"2003","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-201786_ref15","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/carcin\/bgi164","article-title":"Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk","volume":"26","author":"Frank","year":"2005","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.3233\/CBM-201786_ref16","first-page":"242","article-title":"TRAIL gene polymorphism and genetic susceptibility to prostate cancer in the Chinese Han population of Nanjing","volume":"17","author":"Mi","year":"2011","journal-title":"National Journal of Andrology"},{"key":"10.3233\/CBM-201786_ref17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2005.01.021","article-title":"Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer","volume":"97","author":"Horak","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.3233\/CBM-201786_ref18","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1158\/1055-9965.EPI-06-0053","article-title":"Death receptor 4 variants and colorectal cancer risk","volume":"15","author":"Frank","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.3233\/CBM-201786_ref19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/jmv.25476","article-title":"Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma","volume":"91","author":"Zayed","year":"2019","journal-title":"J Med Virol"},{"issue":"3","key":"10.3233\/CBM-201786_ref20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.onc.1204103","article-title":"Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin\u2019s lymphoma","volume":"20","author":"Lee","year":"2001","journal-title":"Oncogene"},{"issue":"7","key":"10.3233\/CBM-201786_ref21","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/ijc.21502","article-title":"Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer","volume":"118","author":"Wolf","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.3233\/CBM-201786_ref22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10428190701713655","article-title":"The role of TRAIL death receptors in the treatment of hematological malignancies","volume":"49","author":"Henson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3233\/CBM-201786_ref23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-013-1864-4","article-title":"Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas","volume":"93","author":"Heredia-Galvez","year":"2014","journal-title":"Ann Hematol"},{"issue":"11","key":"10.3233\/CBM-201786_ref24","first-page":"1322","article-title":"Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms","volume":"89","author":"Fernandez","year":"2004","journal-title":"Haematologica"},{"issue":"14","key":"10.3233\/CBM-201786_ref25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.ejca.2009.06.023","article-title":"TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis","volume":"45","author":"Chen","year":"2009","journal-title":"European Journal of Ancer"},{"key":"10.3233\/CBM-201786_ref26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1997.4393250.x","article-title":"Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies","volume":"99","author":"Snell","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"10.3233\/CBM-201786_ref27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/FPC.0000000000000262","article-title":"Rituximab response in follicular lymphoma is associated withthe rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger","volume":"27","author":"Guti\u00e9rrez-C\u00edvicos","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.3233\/CBM-201786_ref28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL-death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"10.3233\/CBM-201786_ref29","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","article-title":"Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20","volume":"13","author":"Maddipatla","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-201786_ref30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cbpa.2010.07.002","article-title":"Development of antibody surrogates for the treatment of cancers and autoimmune disease","volume":"14","author":"Kodadek","year":"2010","journal-title":"Curr Opin Chem Biol"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-201786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:22Z","timestamp":1777385302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-201786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":30,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/cbm-201786","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}